tetano
Editor, Senior Moderator
Intern Med
. 2022 Sep 28.
doi: 10.2169/internalmedicine.0241-22. Online ahead of print.
Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies
Akihiro Shimizu[SUP] 1 [/SUP], Izumi Shirai[SUP] 1 [/SUP], Kyohei Ogawa[SUP] 1 [/SUP], Akane Miura[SUP] 1 [/SUP], Kotaro Haruhara[SUP] 1 [/SUP], Kentaro Oshiro[SUP] 1 [/SUP], Akihiko Hamaguchi[SUP] 1 [/SUP], Shinya Yokote[SUP] 2 [/SUP], Masahiro Okabe[SUP] 3 [/SUP], Hiroyuki Ueda[SUP] 4 [/SUP], Nobuo Tsuboi[SUP] 4 [/SUP], Masato Ikeda[SUP] 1 [/SUP], Takashi Yokoo[SUP] 4 [/SUP]
Affiliations
Abstract
Rituximab is an effective treatment for frequently relapsing/steroid-dependent nephrotic syndrome, but there is concern about infections caused by humoral immunodeficiency. We herein report a case of prolonged (>7 weeks) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A 24-year-old man with minimal-change disease treated with rituximab developed SARS-CoV-2 infection. The clinical response to remdesivir was soon transiently abolished. Treatment with casirivimab and imdevimab (REGEN-COV) monoclonal antibodies in combination with remdesivir resulted in complete clearance of the infection. The REGEN-COV antibody cocktail may improve the outcome of SARS-CoV-2 infection in patients with humoral immunodeficiency.
Keywords: COVID-19; Minimal change disease; REGEN-COV; frequently relapsing/steroid-dependent nephrotic syndrome; monoclonal antibody therapy; rituximab.
. 2022 Sep 28.
doi: 10.2169/internalmedicine.0241-22. Online ahead of print.
Persistent SARS-CoV-2 Infection in a Patient with Nephrotic Syndrome under Rituximab Therapy: Successful Treatment with a Combination of Remdesivir and Monoclonal Antibodies
Akihiro Shimizu[SUP] 1 [/SUP], Izumi Shirai[SUP] 1 [/SUP], Kyohei Ogawa[SUP] 1 [/SUP], Akane Miura[SUP] 1 [/SUP], Kotaro Haruhara[SUP] 1 [/SUP], Kentaro Oshiro[SUP] 1 [/SUP], Akihiko Hamaguchi[SUP] 1 [/SUP], Shinya Yokote[SUP] 2 [/SUP], Masahiro Okabe[SUP] 3 [/SUP], Hiroyuki Ueda[SUP] 4 [/SUP], Nobuo Tsuboi[SUP] 4 [/SUP], Masato Ikeda[SUP] 1 [/SUP], Takashi Yokoo[SUP] 4 [/SUP]
Affiliations
- PMID: 36171121
- DOI: 10.2169/internalmedicine.0241-22
Abstract
Rituximab is an effective treatment for frequently relapsing/steroid-dependent nephrotic syndrome, but there is concern about infections caused by humoral immunodeficiency. We herein report a case of prolonged (>7 weeks) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A 24-year-old man with minimal-change disease treated with rituximab developed SARS-CoV-2 infection. The clinical response to remdesivir was soon transiently abolished. Treatment with casirivimab and imdevimab (REGEN-COV) monoclonal antibodies in combination with remdesivir resulted in complete clearance of the infection. The REGEN-COV antibody cocktail may improve the outcome of SARS-CoV-2 infection in patients with humoral immunodeficiency.
Keywords: COVID-19; Minimal change disease; REGEN-COV; frequently relapsing/steroid-dependent nephrotic syndrome; monoclonal antibody therapy; rituximab.